The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer

Targeted Oncology

Volumn 9, Issue 2, 2014, Pages 111-122

  Diéras, Véronique ^a   Bachelot, Thomas ^b  

^a INSTITUT CURIE   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

Antibody drug conjugate; Efficacy; Metastatic breast cancer; Pharmacokinetics; Safety; Trastuzumab emtansine

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PACLITAXEL; PERTUZUMAB; PLACEBO; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; MAYTANSINE; MONOCLONAL ANTIBODY;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; BREAST CANCER; CANCER SURVIVAL; CARDIOTOXICITY; CELL SURFACE; CYTOTOXICITY; DIARRHEA; DOWN REGULATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; HUMAN; HYPOKALEMIA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QT PROLONGATION; RASH; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; BREAST NEOPLASMS; FEMALE; GENETICS; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MAYTANSINE; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2;

EID: 84902551521     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0287-4     Document Type: Review

References (65)

1. InVS (2011) Projection de l'incidence et de la mortalité par cancer en France en 2011. http://www.invs.sante.fr/Publications-et-outils/ Rapports-et-syntheses/Maladies-chroniques-et-traumatismes/2011/ Projection-de-l-incidence-et-de-la-mortalite-par-cancer-en-France-en- 2011.
2. Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5(1):63 -69
3. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J (1998) Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol Off J Am Soc Clin Oncol 16(2):462-469 (Pubitemid 28135587)
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177- 182
5. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(36):5658-5663. doi:10.1200/JCO.2006.07.0250 (Pubitemid 46631306)
6. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8(4):307 -325
7. FDA.gov (2006) FDA approval for trastuzumab. http://www.cancer. gov/cancertopics/druginfo/fda-trastuzumab#Anchor-Breast.
8. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357(1):39- 51. doi:10.1056/NEJMra043186
9. Albanell J, Codony J, Rovira A, Mellado B, Gascon P (2003) Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 532:253-268 (Pubitemid 37176793)
10. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61(12):4744-4749 (Pubitemid 32691885)
11. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37(4):255-263 (Pubitemid 23300507)
12. Cooley S, Burns LJ, Repka T, Miller JS (1999) Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27(10):1533-1541 (Pubitemid 29458428)
13. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6(4):443-446. doi:10.1038/74704 (Pubitemid 30208162)
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783-792. doi:10.1056/NEJM200103153441101 (Pubitemid 32222155)
15. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol Off J Am Soc Clin Oncol 23(19):4265-4274. doi:10.1200/JCO.2005.04.173 (Pubitemid 46207001)
16. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110(5):965-972. doi:10.1002/cncr.22885 (Pubitemid 47312860)
17. Eiermann W (2001) Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol Off J Eur Soc Med Oncol / ESMO 12(Suppl 1):S57-62
18. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(18):2786-2792. doi:10.1200/JCO.2005.04.1764 (Pubitemid 46630577)
19. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93(24):1852-1857 (Pubitemid 34048651)
20. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395-402. doi:10.1016/j.ccr.2007.08.030 (Pubitemid 47539306)
21. Nagata Y, Lan KH, Zhou X, TanM, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117- 127. doi:10.1016/j.ccr.2004.06.022
22. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. J Clin Oncol Off J Am Soc Clin Oncol 13(16):4909-4919. doi:10.1158/1078-0432.CCR-07-0701 (Pubitemid 47294799)
23. Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 122(3):685-697. doi:10.1007/s10549-009-0592-x
24. FDA.gov (2007) FDA approval for lapatinib ditosylate. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022059s007lbl.pdf.
25. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O' Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(33):5538 - 5546. doi:10.1200/JCO.2009.23.3734
26. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733-2743. doi:10.1056/NEJMoa064320 (Pubitemid 46021510)
27. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112(3):533- 543. doi:10.1007/s10549-007-9885-0
28. BlackwellKL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, CaseyM, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(7):1124-1130. doi:10.1200/JCO.2008.21.4437
29. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH,Williams LS, Dering J, Finn RS, Press MF (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(34):5544-5552. doi:10.1200/JCO.2008.16.2578
30. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58(13):2825-2831 (Pubitemid 28311914)
31. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, SliwkowskiMX(2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68(22):9280-9290. doi:10.1158/0008-5472.CAN-08-1776
32. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Blattler WA, Chari RV (2006) Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 49(14):4392-4408. doi:10.1021/jm060319f (Pubitemid 44036683)
33. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128(2):347 -356. doi:10.1007/s10549-010-1090-x
34. Issell BF, Crooke ST (1978) Maytansine. Cancer Treat Rev 5(4):199-207 (Pubitemid 9109517)
35. Blum RH, Wittenberg BK, Canellos GP, Mayer RJ, Skarin AT, Henderson IC, Parker LM, Frei E 3rd (1978) A therapeutic trial of maytansine. Cancer Clin Trials 1(2):113-117
36. Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41(1):98-107
37. Lambert JM (2005) Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 5(5):543-549
38. Kovtun YV, Goldmacher VS (2007) Cell killing by antibody-drug conjugates. Cancer Lett 255(2):232-240 (Pubitemid 47268641)
39. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blattler WA (2006) Antibodymaytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66(8):4426-4433. doi:10.1158/0008-5472. CAN-05-4489
40. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15(12):5268-5282. doi:10.1091/mbc.E04-07-0591
41. Barok M, Tanner M, Koninki K, Isola J (2011) Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 13(2):R46. doi:10.1186/bcr2868
42. Lewis Phillips GD, Fields CT, Crocker LM, Parsons K, Tibbitts J, Holden S, Lutzker S, Sliwkowski MX (2008) Potent anti-tumor activity of trastuzumab-DM1 antibodydrug conjugate in combination with cytotoxic chemotherapeutic agents, antibodies or small molecule kinase inhibitors. Paper presented at the 99th AACR Annual Meeting, San Diego
43. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, YuW, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA (2010) Phase I study of trastuzumab-DM1, an HER2 antibodydrug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(16):2698-2704. doi:10.1200/JCO.2009.26.2071
44. Holden SN, Beeram M, Krop IE, Burris HA, Birkner M, Girish S, Tibbitts J, Lutzker SG, Modi S (2008) A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC). Paper presented at the ASCO Annual. Meeting, Chicago
45. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)- positive breast cancer after priorHER2-directed therapy. J Clin Oncol Off J Am Soc Clin Oncol 29(4):398-405. doi:10.1200/JCO.2010.29.5865
46. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Agresta S, Zheng M, Amler L, Rugo H (2009) A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. Paper presented at the San Antonio Breast Cancer Symposium SABCS, San Antonio, TX
47. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Lu M, Burington B, Agresta S, Rugo H (2010) A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy. Paper presented at the European Society for Medical Oncology (ESMO), Milan, Italy
48. Perez EA,Dirix L, Kocsis J, GianniL, Lu J,Vinholes J, Ng V, Linehan C, Agresta S, Hurvitz S (2010) Efficacy and safety of trastuzumab- DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase II study (TDM4450g). Paper presented at the European Society for Medical Oncology (ESMO), Milan, Italy
49. Hurvitz S, Dirix L, Kocsis J, Gianni L, Lu J, Vinholes J, Song C, Tong B, Chu YW, Perez EA (2011) Trastuzumab emtansine (TDM1) vs trastuzumab plus docetaxel (H+T) in previously-untreated HER2-positive metastatic breast cancer (MBC): primary results of a randomized, multicenter, open-label phase II study (TDM4450g/ B021976). Paper presented at the European Multidisciplinary Cancer Congress (EMCC), Stockholm, 23-27 Spetember 2011
50. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol Off J Am Soc Clin Oncol 28(7):1138-1144. doi:10.1200/JCO.2009.24.2024
51. Dieras V, Harbeck N, Albain K, Burris HA, Awada A, Crivellari D, Andre F, Choi YJ, Huang J, Miller KD (2010) A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Paper presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas
52. Miller K, Gianni L, Andre F, Dieras V, Mahtani RL, Harbeck N, Huang JE, Shih T, Choi Y, Burris HA (2010) A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). Paper presented at the ASCO, Chicago
53. Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu YW, Lorusso PM, Girish S (2012) Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine T-DM1: an emphasis on preclinical and clinical catabolism. Current Drug Metabolism
54. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, Tong B, Chu YW, Holden S, Joshi A (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69(5):1229-1240. doi:10.1007/s00280-011-1817-3
55. Gupta M, Lorusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, Joshi A, Girish S (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52(5):691-703. doi:10.1177/0091270011403742
56. Chien AJ, Rugo HS (2010) The cardiac safety of trastuzumab in the treatment of breast cancer. Exp Opin Drug Saf 9(2):335-346. doi:10.1517/ 14740331003627441
57. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83(6):679 -686. doi:10. 4065/83.6.679
58. Gupta M, Wang B, Carrothers TJ, Joshi A, LoRusso PM, Chu W, Shih T, Loecke D, Girish S (2011) Exposure-response analysis in patients with HER2-positive (HER2+) metastatic breast cancer (MBC) to assess the effect of T-DM1 on QTc prolongation. Paper presented at the ASCPT conference Dallas, TX April 3, 2011
59. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK (2003) Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol Off J Am Soc Clin Oncol 21(2):211-222 (Pubitemid 46606149)
60. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783-1791. doi:10. 1056/NEJMoa1209124
61. FDA.gov (2011) FDA approval for brentuximab vedotin. http://www.cancer. gov/cancertopics/druginfo/fda-brentuximabvedotin
62. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 30(18):2183-2189. doi:10.1200/JCO.2011.38.0410
63. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A (2012) Brentuximab vedotin (SGN- 35) in patients with relapsed or refractory systemic anaplastic largecell lymphoma: results of a phase II study. J Clin Oncol Off J Am Soc Clin Oncol 30(18):2190-2196. doi:10.1200/JCO.2011.38. 0402
64. Welslau M, Diéras V, Sohn J, Hurvitz S, Lalla D, Fang L, Guardino E, Miles D (2012) patient-reported outcomes (PROs) from EMILIA, a phase 3 study of trastuzumab emtansine (T-DM1) vs capecitabine and lapatinib (XL) in Her2-positive locally advanced or MBC. Annals of Oncology 23: Supplement 9
65. Bianchi GV, Kocsis J, Dirix L, Torigoe Y, Lalla D, Tong YB, Guardino AE, Hurvitz SA (2011) Patient-reported outcomes (PROs) from a randomized phase II study (TDM4450g/BO21976) of trastuzumab emtansine (T-DM1) vs trastuzumab plus docetaxel (HT) in previously untreated HER2-positive metastatic breast cancer (MBC). Cancer Research 71 (24): Abstract nr P1-12-02. doi:10. 1158/0008-5472.SABCS11-P1-12-02